Hospital
Westchester County Health Care Corporation
Westchester County Health Care Corporation was paid $64.55M by Medicaid between Jan 2018 and Dec 2024, across 486 billing codes. Its largest line is 99283, emergency room visit (moderate) — 10% of everything it billed.
33Billing provider infoWESTCHESTER COUNTY HEALTH CARE CORPORATION
VALHALLA, NY 10595
VALHALLA, NY 10595
33aNPI1932280666assigned 10/18/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$64.55M
24GClaims1,191,678
24DCodes billed486
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New York
Rank by total paid#25 of 231
Median peer was paid$561K
This provider vs. median115×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 11,774 | $338K | |
| 2019 | 70,528 | $3.98M | |
| 2020 | 154,681 | $8.19M | |
| 2021 | 225,768 | $11.78M | |
| 2022 | 253,844 | $13.91M | |
| 2023 | 271,283 | $15.33M | |
| 2024incomplete | 203,800 | $11.02M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 10% | 28,862 | 27,652 | $6.71M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.6% | 25,113 | 23,937 | $4.89M |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 4.6% | 1,861 | 1,851 | $3.00M |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.9% | 8,502 | 7,797 | $2.54M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.7% | 10,479 | 10,122 | $2.41M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 3.2% | 13,480 | 11,414 | $2.04M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.9% | 2,320 | 2,308 | $1.87M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.8% | 9,699 | 9,388 | $1.82M |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 2.7% | 1,007 | 1,006 | $1.75M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.0% | 4,500 | 4,379 | $1.31M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.0% | 9,155 | 7,989 | $1.26M |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 1.8% | 2,938 | 2,854 | $1.18M |
474 more codes
| 80053 | Comprehensive metabolic panel | 1.8% | 70,238 | $1.14M |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 1.7% | 3,024 | $1.09M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.6% | 6,655 | $1.05M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.6% | 7,892 | $1.04M |
| G0378 | Hospital observation service, per hour | 1.6% | 5,802 | $1.03M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.5% | 22,876 | $967K |
| 90834 | Psychotherapy session, about 45 minutes | 1.5% | 6,372 | $947K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | 1.5% | 2,713 | $941K |
| 42830 | 1.4% | 560 | $934K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.4% | 9,854 | $929K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.4% | 3,798 | $920K |
| 41899 | Unlisted procedure, dentoalveolar structures | 1.4% | 659 | $878K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.1% | 2,968 | $732K |
| 86832 | 1.1% | 1,097 | $728K | |
| 86833 | 1.0% | 1,077 | $664K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 841 | $640K |
| 93976 | <1% | 2,450 | $620K | |
| 86850 | <1% | 19,955 | $587K | |
| 44970 | <1% | 200 | $578K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 3,233 | $549K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 5,899 | $468K |
| 86901 | <1% | 22,917 | $443K | |
| 86900 | <1% | 22,939 | $389K | |
| 87486 | <1% | 10,334 | $377K | |
| 74183 | <1% | 1,054 | $366K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 8,196 | $359K |
| 76770 | <1% | 1,282 | $341K | |
| D0140 | Limited oral evaluation - problem focused | <1% | 8,016 | $337K |
| 93970 | <1% | 913 | $275K | |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 4,249 | $275K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 297 | $271K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 870 | $269K |
| 87799 | <1% | 1,672 | $265K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,785 | $254K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 1,256 | $229K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,769 | $228K |
| 36415 | Collection of venous blood by venipuncture | <1% | 66,548 | $225K |
| 72141 | <1% | 711 | $225K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 10,379 | $214K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 5,819 | $206K |
| 87581 | <1% | 10,340 | $198K | |
| 87507 | <1% | 521 | $195K | |
| P9040 | Red blood cells, leukocytes reduced, irradiated, each unit | <1% | 376 | $189K |
| 36430 | <1% | 831 | $188K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,510 | $184K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 6,280 | $176K |
| 88304 | <1% | 3,116 | $170K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 1,615 | $170K |
| 87497 | <1% | 4,879 | $167K | |
| 12011 | <1% | 301 | $162K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,093 | $156K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,775 | $153K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 7,988 | $152K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 5,002 | $149K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,125 | $148K |
| 72197 | <1% | 419 | $147K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 865 | $146K |
| 88342 | <1% | 2,252 | $146K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,018 | $145K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 629 | $141K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 794 | $135K |
| 87536 | <1% | 2,067 | $128K | |
| 86835 | <1% | 292 | $127K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 7,009 | $127K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 4,028 | $127K |
| 85730 | <1% | 19,354 | $124K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 384 | $114K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,472 | $111K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 117 | $109K |
| 70496 | <1% | 372 | $104K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 43,173 | $102K |
| 83970 | <1% | 2,619 | $102K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 4,978 | $100K |
| 88307 | <1% | 871 | $92K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 511 | $88K |
| 96367 | <1% | 932 | $87K | |
| 96450 | <1% | 102 | $86K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,303 | $85K |
| 82784 | <1% | 6,751 | $84K | |
| 72195 | <1% | 201 | $84K | |
| 71250 | <1% | 888 | $81K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 756 | $81K |
| 80061 | Lipid panel | <1% | 9,656 | $81K |
| H0040 | Assertive community treatment program, per diem | <1% | 53 | $79K |
| 86481 | <1% | 1,648 | $79K | |
| 83880 | <1% | 2,618 | $79K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,973 | $79K |
| 76775 | <1% | 1,382 | $77K | |
| 12001 | <1% | 144 | $77K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 8,469 | $76K |
| 82728 | <1% | 6,339 | $75K | |
| 82610 | <1% | 1,051 | $75K | |
| 83735 | <1% | 20,009 | $74K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 9,668 | $73K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 742 | $72K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 429 | $72K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 8,717 | $69K |
| 86003 | <1% | 1,834 | $68K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,218 | $67K |
| D2930 | Prefabricated stainless steel crown - primary tooth | <1% | 121 | $64K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 8,953 | $64K |
| 85610 | <1% | 21,651 | $63K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 363 | $62K |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 850 | $61K |
| 90836 | <1% | 539 | $56K | |
| 72146 | <1% | 202 | $55K | |
| 88300 | <1% | 1,701 | $54K | |
| 80197 | <1% | 6,177 | $54K | |
| 83615 | <1% | 12,737 | $53K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,508 | $52K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 3,955 | $51K |
| 84100 | <1% | 14,481 | $51K | |
| 86360 | <1% | 1,436 | $50K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,852 | $50K |
| 76641 | <1% | 1,838 | $49K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 269 | $48K |
| 88142 | <1% | 2,247 | $48K | |
| 82805 | <1% | 2,634 | $48K | |
| 86923 | <1% | 271 | $47K | |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 285 | $46K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 647 | $45K |
| D9430 | <1% | 1,041 | $45K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 707 | $44K |
| 88112 | <1% | 782 | $44K | |
| 85027 | <1% | 17,740 | $41K | |
| D0330 | Panoramic radiographic image | <1% | 2,356 | $40K |
| 94060 | <1% | 1,468 | $40K | |
| 74230 | <1% | 209 | $40K | |
| 86317 | <1% | 265 | $38K | |
| 86359 | <1% | 1,421 | $38K | |
| 86769 | <1% | 1,113 | $38K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 716 | $38K |
| 59025 | Fetal non-stress test | <1% | 132 | $37K |
| 86480 | <1% | 655 | $36K | |
| 87522 | Neg quan hep c or qual rna | <1% | 983 | $36K |
| 84550 | <1% | 9,834 | $36K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 9,644 | $35K |
| 87517 | <1% | 316 | $35K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 202 | $35K |
| 70486 | <1% | 355 | $34K | |
| 84439 | <1% | 4,606 | $34K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 8,527 | $34K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,522 | $32K |
| 81001 | <1% | 15,735 | $32K | |
| 82607 | <1% | 3,052 | $32K | |
| 87340 | <1% | 4,087 | $31K | |
| 94726 | <1% | 1,717 | $31K | |
| 0012A | <1% | 984 | $31K | |
| 87077 | <1% | 5,136 | $30K | |
| 87070 | <1% | 5,619 | $30K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 65 | $30K |
| 83021 | <1% | 1,649 | $30K | |
| 94729 | <1% | 1,824 | $29K | |
| 54640 | <1% | 26 | $29K | |
| 83540 | <1% | 6,341 | $29K | |
| 84702 | <1% | 3,800 | $28K | |
| 83550 | <1% | 6,085 | $27K | |
| 82570 | <1% | 6,426 | $27K | |
| 85576 | <1% | 1,084 | $27K | |
| 80321 | <1% | 1,004 | $27K | |
| 88341 | <1% | 550 | $26K | |
| 86803 | <1% | 3,418 | $25K | |
| 96415 | <1% | 54 | $24K | |
| 82803 | <1% | 847 | $24K | |
| 86160 | <1% | 2,448 | $22K | |
| 0011A | <1% | 864 | $22K | |
| 86140 | <1% | 8,758 | $21K | |
| 92611 | <1% | 139 | $21K | |
| 74240 | <1% | 486 | $21K | |
| 82746 | <1% | 1,911 | $20K | |
| 84156 | <1% | 6,147 | $19K | |
| 83655 | <1% | 1,413 | $19K | |
| 82977 | <1% | 3,900 | $18K | |
| 84153 | <1% | 1,145 | $18K | |
| D0150 | Comprehensive oral evaluation - new or established patient | <1% | 317 | $17K |
| 72158 | <1% | 52 | $17K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 98 | $17K |
| 97161 | <1% | 155 | $17K | |
| 51600 | <1% | 55 | $17K | |
| 76818 | <1% | 240 | $17K | |
| 84403 | <1% | 679 | $16K | |
| 82248 | <1% | 4,232 | $16K | |
| 93971 | <1% | 209 | $16K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 4,015 | $16K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,003 | $16K |
| 85007 | <1% | 12,306 | $15K | |
| 86765 | <1% | 1,297 | $15K | |
| 96376 | <1% | 1,590 | $14K | |
| 90686 | <1% | 591 | $14K | |
| 86665 | <1% | 1,104 | $14K | |
| 86706 | <1% | 2,061 | $14K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 12 | $14K |
| 86704 | <1% | 1,760 | $13K | |
| 86880 | <1% | 1,028 | $13K | |
| 76536 | <1% | 342 | $13K | |
| 87186 | <1% | 3,022 | $13K | |
| 82785 | <1% | 1,030 | $13K | |
| 86364 | <1% | 1,752 | $12K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,258 | $12K |
| 85384 | <1% | 2,415 | $12K | |
| 95816 | <1% | 70 | $12K | |
| 86780 | <1% | 1,489 | $12K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 12 | $12K |
| 95782 | <1% | 12 | $12K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 21 | $12K |
| G0390 | Trauma response team associated with hospital critical care service | <1% | 163 | $11K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 341 | $11K |
| 94010 | <1% | 303 | $11K | |
| 76870 | <1% | 289 | $10K | |
| 74455 | <1% | 78 | $10K | |
| 85651 | <1% | 6,614 | $10K | |
| 85045 | <1% | 3,475 | $10K | |
| 70546 | <1% | 29 | $10K | |
| 82105 | <1% | 1,522 | $10K | |
| 83002 | <1% | 574 | $10K | |
| 25605 | <1% | 16 | $10K | |
| 85240 | <1% | 904 | $9K | |
| 86762 | <1% | 746 | $9K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 27 | $9K |
| 86357 | <1% | 391 | $9K | |
| 86038 | <1% | 1,867 | $9K | |
| 86355 | <1% | 382 | $9K | |
| 0002A | <1% | 265 | $9K | |
| 0001A | <1% | 260 | $9K | |
| 16020 | <1% | 15 | $9K | |
| 83001 | <1% | 519 | $9K | |
| 84703 | <1% | 5,550 | $9K | |
| 83690 | <1% | 5,283 | $8K | |
| 72156 | <1% | 28 | $8K | |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 95 | $8K |
| 82947 | <1% | 8,157 | $8K | |
| D1110 | Prophylaxis - adult | <1% | 128 | $8K |
| 82670 | <1% | 299 | $8K | |
| 95819 | <1% | 40 | $8K | |
| 76801 | <1% | 95 | $8K | |
| 85246 | <1% | 667 | $8K | |
| 84402 | <1% | 321 | $8K | |
| 82378 | <1% | 433 | $8K | |
| 92604 | <1% | 68 | $7K | |
| 85245 | <1% | 589 | $7K | |
| 86376 | <1% | 558 | $7K | |
| 70491 | <1% | 25 | $7K | |
| 86787 | <1% | 953 | $7K | |
| 86592 | <1% | 2,180 | $7K | |
| 77072 | <1% | 551 | $7K | |
| 86147 | <1% | 770 | $7K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 155 | $6K |
| 81003 | <1% | 5,432 | $6K | |
| 76820 | <1% | 321 | $6K | |
| 84146 | <1% | 385 | $6K | |
| 74018 | <1% | 1,419 | $6K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 247 | $6K |
| 72082 | <1% | 449 | $6K | |
| 82077 | <1% | 213 | $6K | |
| 70498 | <1% | 66 | $6K | |
| 86618 | <1% | 562 | $6K | |
| 86235 | <1% | 696 | $6K | |
| 86708 | <1% | 779 | $6K | |
| 88302 | <1% | 98 | $6K | |
| 86735 | <1% | 747 | $6K | |
| 93320 | <1% | 156 | $5K | |
| 82550 | <1% | 2,351 | $5K | |
| 83010 | <1% | 481 | $5K | |
| 80069 | <1% | 632 | $5K | |
| 85379 | <1% | 1,376 | $5K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 24 | $5K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 241 | $5K |
| 87254 | <1% | 650 | $5K | |
| 74021 | <1% | 667 | $5K | |
| 80076 | <1% | 520 | $5K | |
| 80320 | <1% | 1,820 | $5K | |
| 90715 | <1% | 220 | $5K | |
| 73130 | <1% | 736 | $4K | |
| 86644 | <1% | 375 | $4K | |
| 95716 | <1% | 33 | $4K | |
| 82043 | <1% | 963 | $4K | |
| 84484 | <1% | 4,072 | $4K | |
| 92567 | <1% | 75 | $4K | |
| 84480 | <1% | 834 | $4K | |
| 72157 | <1% | 12 | $4K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 15 | $4K |
| 82330 | <1% | 2,124 | $4K | |
| 73610 | <1% | 766 | $4K | |
| 86225 | <1% | 745 | $4K | |
| 82150 | <1% | 2,865 | $4K | |
| 84145 | <1% | 1,431 | $4K | |
| 87205 | <1% | 1,482 | $4K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,615 | $4K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 732 | $3K |
| 83605 | <1% | 3,315 | $3K | |
| 93325 | <1% | 176 | $3K | |
| 73560 | <1% | 547 | $3K | |
| J2704 | Injection, propofol, 10 mg | <1% | 10,398 | $3K |
| D0210 | Intraoral - complete series of radiographic images | <1% | 57 | $3K |
| C1769 | Guide wire | <1% | 764 | $3K |
| 87040 | <1% | 3,925 | $3K | |
| 84590 | <1% | 312 | $3K | |
| 87338 | <1% | 373 | $3K | |
| 84305 | <1% | 135 | $3K | |
| 93017 | <1% | 94 | $3K | |
| 73110 | <1% | 528 | $3K | |
| 85247 | <1% | 214 | $3K | |
| 70544 | <1% | 13 | $3K | |
| 84436 | <1% | 1,090 | $3K | |
| 86231 | <1% | 359 | $3K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 2,168 | $3K |
| 86039 | <1% | 532 | $3K | |
| 73562 | <1% | 310 | $3K | |
| 83521 | <1% | 156 | $2K | |
| 83003 | <1% | 70 | $2K | |
| 95715 | <1% | 41 | $2K | |
| 82950 | <1% | 518 | $2K | |
| 86870 | <1% | 73 | $2K | |
| 88313 | <1% | 226 | $2K | |
| 86431 | <1% | 477 | $2K | |
| 74174 | <1% | 17 | $2K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 56 | $2K |
| 73090 | <1% | 715 | $2K | |
| 73700 | <1% | 18 | $2K | |
| 95700 | <1% | 60 | $2K | |
| 84446 | <1% | 181 | $2K | |
| 83516 | <1% | 52 | $2K | |
| 73030 | <1% | 313 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,206 | $2K |
| 84425 | <1% | 138 | $2K | |
| 82533 | <1% | 188 | $2K | |
| 73630 | <1% | 387 | $2K | |
| 72170 | <1% | 298 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 359 | $2K |
| 83993 | <1% | 156 | $2K | |
| 90750 | <1% | 13 | $2K | |
| 90688 | <1% | 57 | $2K | |
| 75574 | <1% | 12 | $2K | |
| 86301 | <1% | 93 | $2K | |
| 86146 | <1% | 157 | $1K | |
| 87185 | <1% | 410 | $1K | |
| 84630 | <1% | 205 | $1K | |
| 86800 | <1% | 115 | $1K | |
| 73590 | <1% | 496 | $1K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,252 | $1K |
| 77073 | <1% | 66 | $1K | |
| 84154 | <1% | 111 | $1K | |
| D0220 | Intraoral - periapical first radiographic image | <1% | 128 | $1K |
| 84207 | <1% | 50 | $1K | |
| 70480 | <1% | 12 | $1K | |
| 85055 | <1% | 48 | $1K | |
| 94760 | <1% | 266 | $1K | |
| 73521 | <1% | 210 | $1K | |
| 87177 | <1% | 136 | $1K | |
| 0064A | <1% | 31 | $1K | |
| 86334 | <1% | 56 | $1K | |
| J3490 | Unclassified drugs | <1% | 653 | $1K |
| 72100 | <1% | 107 | $1K | |
| 82565 | <1% | 243 | $1K | |
| 77066 | Tomosynthesis, mammo | <1% | 15 | $1K |
| 86304 | <1% | 53 | $1K | |
| 82438 | <1% | 230 | $1K | |
| 82103 | <1% | 87 | $975.05 | |
| 73552 | <1% | 178 | $950.69 | |
| 87209 | <1% | 155 | $895.26 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,557 | $891.48 |
| 86015 | <1% | 135 | $828.49 | |
| 89230 | <1% | 131 | $794.73 | |
| 73070 | <1% | 242 | $776.79 | |
| 73080 | <1% | 127 | $754.85 | |
| D0230 | Intraoral - periapical each additional radiographic image | <1% | 39 | $748.82 |
| 83525 | <1% | 61 | $708.66 | |
| 80329 | <1% | 116 | $695.00 | |
| 82390 | <1% | 95 | $684.65 | |
| 84132 | <1% | 2,181 | $681.41 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 10,069 | $668.78 |
| 82787 | <1% | 52 | $625.56 | |
| 77080 | <1% | 12 | $606.00 | |
| 90656 | <1% | 45 | $593.66 | |
| 86255 | <1% | 62 | $566.80 | |
| 84295 | <1% | 2,128 | $555.99 | |
| C9399 | Unclassified drugs or biologicals | <1% | 551 | $550.80 |
| 85732 | <1% | 81 | $513.18 | |
| 90461 | <1% | 74 | $476.80 | |
| 85290 | <1% | 54 | $472.98 | |
| 72040 | <1% | 84 | $471.37 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 904 | $468.83 |
| 82525 | <1% | 51 | $465.86 | |
| 83519 | <1% | 14 | $450.07 | |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | <1% | 212 | $444.37 |
| 87106 | <1% | 49 | $419.70 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 496 | $407.90 |
| 73060 | <1% | 76 | $407.31 | |
| 94621 | <1% | 13 | $389.48 | |
| 0031A | <1% | 28 | $357.21 | |
| 82465 | <1% | 92 | $336.87 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,587 | $335.87 |
| 82104 | <1% | 27 | $333.39 | |
| 73502 | <1% | 62 | $316.60 | |
| L8699 | Prosthetic implant, not otherwise specified | <1% | 631 | $316.27 |
| 81050 | <1% | 25 | $315.58 | |
| 87493 | <1% | 15 | $313.21 | |
| 94770 | <1% | 43 | $301.66 | |
| 86709 | <1% | 39 | $295.76 | |
| 86258 | <1% | 51 | $287.94 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 111 | $250.78 |
| 76857 | <1% | 13 | $242.80 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 13 | $240.00 |
| 90633 | <1% | 12 | $214.20 | |
| 85250 | <1% | 12 | $213.25 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,104 | $206.71 |
| 85613 | <1% | 27 | $204.54 | |
| 87081 | <1% | 90 | $202.44 | |
| 89051 | <1% | 141 | $201.38 | |
| 86849 | <1% | 12 | $172.20 | |
| 87807 | <1% | 196 | $168.73 | |
| 82272 | <1% | 13 | $156.69 | |
| A4649 | Surgical supply; miscellaneous | <1% | 212 | $152.34 |
| 82553 | <1% | 117 | $149.89 | |
| 82139 | <1% | 14 | $144.13 | |
| 87147 | <1% | 59 | $137.46 | |
| 96523 | <1% | 72 | $135.22 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 8,603 | $133.86 |
| J3535 | Drug administered through a metered dose inhaler | <1% | 77 | $109.60 |
| 83718 | <1% | 47 | $102.51 | |
| 84466 | <1% | 16 | $101.04 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,560 | $98.74 |
| 86036 | <1% | 19 | $94.90 | |
| 73000 | <1% | 14 | $90.87 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,617 | $90.62 |
| 82951 | <1% | 14 | $88.82 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,280 | $86.27 |
| 82140 | <1% | 27 | $83.05 | |
| 84481 | <1% | 16 | $80.48 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 993 | $74.22 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 460 | $72.36 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,028 | $70.83 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 795 | $70.08 |
| 87045 | <1% | 12 | $58.97 | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 235 | $53.28 |
| 83930 | <1% | 86 | $48.56 | |
| 87046 | <1% | 24 | $48.31 | |
| 84520 | <1% | 12 | $46.98 | |
| J9250 | Methotrexate sodium, 5 mg | <1% | 28 | $44.24 |
| 86705 | <1% | 14 | $41.94 | |
| C1729 | Catheter, drainage | <1% | 64 | $37.59 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 515 | $30.57 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 1,597 | $26.74 |
| 87075 | <1% | 13 | $23.82 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 66 | $20.97 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 15 | $16.12 |
| 82945 | <1% | 17 | $14.55 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 385 | $13.72 |
| 84157 | <1% | 17 | $13.59 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 862 | $12.67 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 134 | $10.27 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 99 | $8.89 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 132 | $8.61 |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 136 | $8.20 |
| C1776 | Joint device (implantable) | <1% | 33 | $4.02 |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 12 | $2.91 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 24 | $2.52 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 13 | $1.44 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 47 | $1.08 |
| 94799 | <1% | 85 | $1.01 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 299 | $0.38 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 20 | $0.09 |
| L8613 | Ossicula implant | 0% | 78 | $0.00 |
| 99080 | 0% | 3,953 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 65 | $0.00 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 133 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 13 | $0.00 |
| 90472 | Immunization administration, each additional vaccine (list separately) | 0% | 13 | $0.00 |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | 0% | 103 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 81 | $0.00 |
| C1781 | Mesh (implantable) | 0% | 54 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 49 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 13 | $0.00 |
| 82657 | 0% | 24 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDESAI, VISHAL (SENIOR VICE PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Westchester County Health Care Corporation | Poughkeepsie, NY | $19.58M |
| Westchester County Health Care Corporation | Valhalla, NY | $40K |
| Westchester County Health Care Corporation | Poughkeepsie, NY | $10K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.